Stocktoria
Aptorum Group Ltd APM
Aptorum Group Ltd (APM) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.95 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| APM | Aptorum Group Ltd | 2/9 | — | — | — |
| TMO | THERMO FISHER SCIENTIFIC INC. | 5/9 | 4.01 | 28.4 | +3.9% |
| ROK | ROCKWELL AUTOMATION, INC | 7/9 | 3.39 | 61.1 | +0.9% |
| TRMB | TRIMBLE INC. | 4/9 | 3.47 | 27.9 | -2.6% |
| ONTO | ONTO INNOVATION INC. | 3/9 | 12.57 | 117.8 | +1.8% |
| GEOS | GEOSPACE TECHNOLOGIES CORP | 1/9 | 8.01 | — | -18.3% |
| OWLT | Owlet, Inc. | 4/9 | -9.08 | — | +35.4% |
About Aptorum Group Ltd
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
FAQ
Is APM financially healthy?
Aptorum Group Ltd's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does APM pay a dividend?
No, Aptorum Group Ltd does not currently pay a dividend.
How profitable is APM?
In FY2025, Aptorum Group Ltd had a return on equity of -5.9%.
Is APM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aptorum Group Ltd: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.